Changes of Serum Omentin Levels and Relationship between Omentin and Adiponectin Concentrations in Type 2 Diabetes Mellitus

Abstract

Background: Omentin has recently been characterized as a potent insulin-sensitizing adipokine, but its pathophysiologic roles in humans remain largely unknown.

Objective: To investigate the change of fasting serum omentin levels and evaluate the relationship of omentin with adiponectin in patients with type 2 diabetes mellitus.

Design: 35 patients with newly diagnosed type 2 diabetes (T2DM), 35 patients with impaired glucose regulation (IGT) and 35 patients with normal glucose tolerance (NGT) participated in this study. Fasting serum omentin and adiponectin levels were measured by enzyme-linked immunosorbent assay. The relationship between serum omentin, serum adiponectin levels and metabolic parameters was also analyzed.

Results: Fasting serum omentin levels were significantly lower in T2DM and IGT groups than in NGT group (16.75±1.71 vs. 18.62±1.22 vs. 24.60±1.43 ng/ml, all P<0.01). Obesity subjects had significantly lower serum omentin levels than normal body weight subjects (P<0.01 or P<0.05). Female subjects had moderately higher fasting serum omentin levels than male subjects. Fasting serum adiponectin levels showed a similar variation trend to omentin in T2DM and NGT groups, obesity and normal body weight subjects, female and male subjects. Fasting serum omentin levels were negatively correlated with HOMA-IR and positively correlated with adiponectin. Moreover, HOMA-IR and adiponectin were the independently predictors of fasting serum omentin levels.

Conclusions: Serum omentin levels possibly play an important role in the pathogenesis of insulin resistance and diabetes. More importantly, there is such a close connection between serum omentin and adiponectin levels that regulation of omentin may be dependent on adiponectin.

Key words

omentin - adiponectin - type 2 diabetes - insulin resistance associated with obesity

References

• 1 Ahima RS, Lazar MA. Adipokines and the peripheral and neural control of energy balance.  Mol Endocrinol. 2008;  22 1023-1031
• 2 Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its Complications. Part 1: diagnosis and classification of mellitus, provisional report of a WHO consultation.  Diabet Med. 1998;  15 539-553
• 3 Bacha F, Saad R, Gungor N. et al . Adiponectin in youth: relationship to visceral adiposity, insulin sensitivity, and beta-cell function.  Diabetes Care. 2004;  27 547-552
• 4 Cai RC, Wei L, Di JZ. et al . Expression of omentin in adipose tissues in obese and type 2 diabetic patients.  Zhonghua Yi Xue Za Zhi. 2009;  89 381-384
• 5 Cnop M, Havel PJ, Utzschneider KM. et al . Relationship of adiponectin to body fat distribution, insulin sensitivity and plasma lipoproteins: evidence for independent roles of age and sex.  Diabetologia. 2003;  46 459-469
• 6 Daimon M, Oizumi T, Saitoh T. et al . Decreased serum levels of adiponectin are a risk factor for the progression to type 2 diabetes in the Japanese Population: the Funagata study.  Diabetes Care. 2003;  26 2015-2020
• 7 de Souza Batista CM, Yang RZ, Lee MJ. et al . Omentin plasma levels and gene expression are decrease in obesity.  Diabetes. 2007;  56 1655-1661
• 8 Duncan BB, Schmidt MI, Pankow JS. et al . Adiponectin and the development of type 2 diabetes: the atherosclerosis risk in communities study.  Diabetes. 2004;  53 2473-2478
• 9 Elbein SC, Hoffman MD, Teng K. et al . A genome-wide search for type 2 diabetes susceptibility genes in Utah Caucasians.  Diabetes. 1999;  48 1175-1182
• 10 Fu M, Gong DW, Damcott C. et al . Systematic analysis of omentin 1 and omentin 2 on 1q23 as candidate genes for type 2 diabetes in the Old Order Amish (Abstract).  Diabetes. 2004;  53 A59
• 11 Fukuhara A, Matsuda M, Nishizawa M. et al . Visfatin: a protein secreted by visceral fat that mimics the effects of insulin.  Science. 2005;  307 426-430
• 12 Gale SM, Castracane VD, Mantzoros CS. Energy homeostasis, obesity and eating disorders: recent advances in endocrinology.  J Nutr. 2004;  134 295-298
• 13 Gilardini L, McTernan PG, Girola A. et al . Adiponectin is a candidate marker of metabolic syndrome in obese children and adolescents.  Atherosclerosis. 2006;  189 401-407
• 14 Haluzík M, Parízková J, Haluzík MM. Adiponectin and its role in the obesity-induced insulin resistance and related complications.  Physiol Res. 2004;  53 123-129
• 15 Hanley AJ, Bowden D, Wagenknecht LE. et al . Associations of adiponectin with body fat distribution and insulin sensitivity in nondiabetic Hispanics and African-Americans.  J Clin Endocrinol Metab. 2007;  92 2665-2671
• 16 Hanson RL, Ehm MG, Pettitt DJ. et al . An autosomal genomic scan for loci linked to type II diabetes mellitus and body-mass index in Pima Indians.  Am J Hum Genet. 1998;  63 1130-1138
• 17 Heidemann C, Sun Q, van Dam RM. et al . Total and high-molecular-weight adiponectin and resistin in relation to the risk for type 2 diabetes in women.  Ann Intern Med. 2008;  149 307-316
• 18 Hivert MF, Sullivan LM, Fox CS. et al . Associations of adiponectin, resistin, and tumor necrosis factor-α with insulin resistance.  J Clin Endocrinol Metab. 2008;  93 3165-3172
• 19 Hotta K, Funahashi T, Arita Y. et al . Plasma concentrations of a novel, Adipose-specific protein, adiponectin, in type 2 diabetic patients.  Arterioscler Thromb Vasc Biol. 2000;  20 1595-1599
• 20 Kase H, Hattori Y, Jojima T. et al . Globular adiponectin induces adhesion molecule expression through the sphingosine kinase pathway in vascular endothelial cells.  Life Sci. 2007;  81 939-943
• 21 Kershaw EE, Flier JS. Adipose tissue as an endocrine organ.  J Clin Endocrinol Metab. 2004;  89 2548-2556
• 22 Krakoff J, Funahashi T, Stehouwer CD. et al . Inflammatory markers, adiponectin, and risk of type 2 diabetes in the Pima Indian.  Diabetes Care. 2003;  26 1745-1751
• 23 Kralisch S, Klein J, Bluher M. et al . Therapeutic perspectives of adipocytokines.  Expert Opin Pharmacother. 2005;  6 863-872
• 24 Lindsay RS, Funahashi T, Hanson RL. et al . Adiponectin and development of type 2 diabetes in the Pima Indian population.  Lancet. 2002;  360 57-58
• 25 Lorenzo M, Ferna’ndez-Veledo S, Vila-Bedmar R. et al . Insulin resistance induced by tumor necrosis factor-α in myocytes and brown adipocytes.  J Anim Sci. 2008;  86 E94-E104
• 26 Masaie H, Oritani K, Yokota T. et al . Adiponectin binds to chemokines via the globular head and modulates interactions between chemokines and heparan sulfates.  Exp Hematol. 2007;  35 947-956
• 27 Mather KJ, Funahashi T, Matsuzawa Y. et al . Adiponectin, change in adiponectin, and progression to diabetes in the Diabetes Prevention Program.  Diabetes. 2008;  57 980-986
• 28 Matsubara M, Maruoka S, Katayose S. Decreased plasma adiponectin concentrations in women with dyslipidemia.  J Clin Endocrinol Metab. 2002;  87 2764-2769
• 29 Matthews DR, Hosker JP, Rudenski AS. et al . Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man.  Diabetologia. 1985;  28 412-419
• 30 McLaughlin T, Abbasi F, Kim HS. et al . Relationship between insulin resistance, weight loss, and coronary heart disease risk in healthy, obese women.  Metabolism. 2001;  50 795-800
• 31 Mertens I, Ballaux D, Funahashi T. et al . Inverse relationship between plasminogen activator inhibitor-I activity and adiponectin in overweight and obese women. Interrelationship with visceral adipose tissue, insulin resistance, HDL-chol and inflammation.  Thromb Haemost. 2005;  94 1190-1195
• 32 Mohan V, Deepa R, Pradeepa R. et al . Association of low adiponectin levels with the metabolic syndrome – the Chennai Urban Rural Epidemiology Study (CURES-4).  Metabolism. 2005;  54 476-481
• 33 Neumeier M, Weigert J, Schäffler A. et al . Different effects of adiponectin isoforms in human monocytic cells.  J Leukoc Biol. 2006;  79 803-808
• 34 Okamoto Y, Kihara S, Funahashi T. et al . Adiponectin: a key adipocytokine in metabolic syndrome.  Clin Sci. 2006;  110 267-278
• 35 Pan HY, Guo L, Li Q. Changes of serum omentin-1 levels in normal subjects and in patients with impaired glucose regulation and with newly diagnosed and untreated type 2 diabetes.  Diabetes Res Clin Pract. 2010;  88 29-33
• 36 Pellmé F, Smith U, Funahashi T. et al . Circulating adiponectin levels are reduced in nonobese but insulin-resistant first-degree relatives of type 2 diabetic patients.  Diabetes. 2003;  52 1182-1186
• 37 Rashid S, Watanabe T, Sakaue T. et al . Mechanisms of HDL lowering in insulin resistant, hypertriglyceridemic states: the combined effect of HDL triglyceride enrichment and elevated hepatic lipase activity.  Clin Biochem. 2003;  36 421-429
• 38 Schäffler A, Neumeier M, Herfarth H. et al . Genomic structure of human omentin, a new adipocytokine expressed in omental adipose tissue.  Biochim Biophys Acta. 2005;  1732 96-102
• 39 Sell H, Dietze-Schroeder D, Eckardt K. et al . Cytokine secretion by human adipocytes is differentially regulated by adiponectin, AICAR, and troglitazone.  Biochem Biophys Res Commun. 2006;  343 700-706
• 40 Snehalatha C, Mukesh B, Simon M. et al . Plasma adiponectin is an independent predictor of type 2 diabetes in Asian Indians.  Diabetes Care. 2003;  26 3226-3229
• 41 Snijder MB, Heine RJ, Seidell JC. et al . Associations of adiponectin levels with incident impaired glucose metabolism and type 2 diabetes in older men and women: The hoorn study.  Diabetes Care. 2006;  29 2498-2503
• 42 Spranger J, Kroke A, Möhlig M. et al . Adiponectin and protection against type 2 diabetes mellitus.  Lancet. 2003;  361 226-228
• 43 St Jean P, Husueh WC, Mitchell B. et al . Association between diabetes, obesity, glucose and inulin levels in the Old Oder Amish and SNPs on 1q21-23.  Am J Hum Genet. 2000;  67 332-337
• 44 Tan BK, Adya R, Farhatullah S. et al . Omentin-1, a novel adipokine, is decreased in overweight insulin-resistant women with polycystic ovary syndrome ex vivo and in vivo regulation of omentin-1 by insulin and glucose.  Diabetes. 2008;  57 801-808
• 45 Tan BK, Pua S, Syed F. et al . Decreased plasma omentin-1 levels in Type 1 diabetes mellitus.  Diabet Med. 2008;  25 1254-1255
• 46 Tschritter O, Fritsche A, Thamer C. et al . Plasma adiponectin concentrations predict insulin sensitivity of both glucose and lipid metabolism.  Diabetes. 2003;  52 239-243
• 47 Vionnet N, Hani EH, Dupont S. et al . Genomewide search for type 2 diabetes-susceptibility genes in French whites: evidence for a novel susceptibility locus for early-onset diabetes on chromosome 3q27-qter and independent replication of a type 2-diabetes locus on chromosome 1q21-q24.  Am J Hum Genet. 2000;  67 1470-1480
• 48 Wang J, Li H, Franco OH. et al . Adiponectin and metabolic syndrome in middle-aged and elderly Chinese.  Obesity. 2008;  16 172-178
• 49 Wannamethee SG, Lowe GD, Rumley A. et al . Adipokines and risk of type 2 diabetes in older men.  Diabetes Care. 2007;  30 1200-1205
• 50 Weyer C, Funahashi T, Tanaka S. et al . Hypoadiponectinemia in obesity and type 2 diabetes: close association with insulin resistance and hyperinsulinemia.  J Clin Endocrinol Metab. 2001;  86 1930-1935
• 51 Wiltshire S, Hattersley AT, Hitman GA. et al . A genomewide scan for loci predisposing to type 2 diabetes in a U.K. population (the Diabetes UK Warren 2 Repository): analysis of 573 pedigrees provides independent replication of a susceptibility locus on chromosome 1q.  Am J Hum Genet. 2001;  69 553-569
• 52 Winzer C, Wagner O, Festa A. et al . Plasma adiponectin, insulin sensitivity, and subclinical inflammation in women with prior gestational diabetes mellitus.  Diabetes Care. 2004;  27 1721-1727
• 53 Xiang K, Wang Y, Zheng T. et al . Genome-wide search for type 2 diabetes/impaired glucose homeostasis susceptibility genes in the Chinese: significant linkage to chromosome 6q21-q23 and chromosome 1q21-q24.  Diabetes. 2004;  53 228-234
• 54 Yamauchi T, Kamon J, Waki H. et al . The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity.  Nat Med. 2001;  7 941-946
• 55 Yang R, Xu A, Pray J. et al . Cloning of omentin, a new adipocytokine from omental fat tissue in humans.  Diabetes. 2003;  (Suppl.1) A1
• 56 Yang RZ, Lee MJ, Hu H. et al . Identification of omentin as a novel depot-specific adipokine in human adipose tissue: possible role in modulating insulin action.  Am J Physiol Endocrinol Metab. 2006;  290 E1253-E1261
• 57 Zoccali C, Mallamaci F, Tripepi G. et al . Adiponectin, metabolic risk factors, and cardiovascular events among patients with end-stage renal disease.  J Am Soc Nephrol. 2002;  13 134-141

Correspondence